Bevacizumab is safe in acute relapses of neuromyelitis optica

Maureen A. Mealy, Kyong Shin, Gareth John, Michael Levy

Research output: Contribution to journalArticle

Abstract

Objectives Neuromyelitis optica (NMO) is a relapsing autoimmune disease targeting the spinal cord and optic nerve leading to paralysis and blindness. Current treatment for acute NMO attacks is immunosuppression with high-dose corticosteroids and/or plasmapheresis. Preclinical animal studies suggest that bevacizumab might be beneficial in limiting the extent of inflammation during a NMO relapse by reducing the disruption of the blood-brain barrier. Methods We carried out an open-label phase 1b safety and proof-of-concept trial in 10 participants with NMO immunoglobulin G seropositive NMO, NMO spectrum disease and those at high risk for developing NMO/NMO spectrum disease who presented with an acute attack of transverse myelitis, optic neuritis or brainstem inflammation. In addition to treating with 1 g of daily intravenous methylprednisolone, we infused 10 mg/kg of bevacizumab intravenously on day 1 of treatment. The primary outcome measure was safety and the secondary outcome measure was efficacy. Results Of the 10 participants enrolled, five presented with acute transverse myelitis, four with acute optic neuritis and one with a brainstem lesion. Bevacizumab was safe in all 10 participants, with only one serious adverse event within the 90-day follow up that was not attributed to the medication. Three patients recovered to pre-attack neurological function or better, and no patients required escalation to plasmapheresis. Conclusions Bevacizumab is a safe add-on therapy to high-dose corticosteroids for NMO/NMO spectrum disease patients presenting with an acute relapse.

Original languageEnglish (US)
Pages (from-to)413-418
Number of pages6
JournalClinical and Experimental Neuroimmunology
Volume6
Issue number4
DOIs
StatePublished - Nov 1 2015

Fingerprint

Neuromyelitis Optica
Recurrence
Transverse Myelitis
Optic Neuritis
Plasmapheresis
Brain Stem
Adrenal Cortex Hormones
Outcome Assessment (Health Care)
Bevacizumab
Inflammation
Safety
Spinal Nerves
Methylprednisolone
Blindness
Optic Nerve
Blood-Brain Barrier
Paralysis
Immunosuppression
Autoimmune Diseases
Spinal Cord

Keywords

  • aquaporin-4
  • bevacizumab
  • neuromyelitis optica
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Clinical Neurology
  • Immunology and Microbiology (miscellaneous)
  • Neuroscience (miscellaneous)
  • Immunology

Cite this

Bevacizumab is safe in acute relapses of neuromyelitis optica. / Mealy, Maureen A.; Shin, Kyong; John, Gareth; Levy, Michael.

In: Clinical and Experimental Neuroimmunology, Vol. 6, No. 4, 01.11.2015, p. 413-418.

Research output: Contribution to journalArticle

Mealy, Maureen A. ; Shin, Kyong ; John, Gareth ; Levy, Michael. / Bevacizumab is safe in acute relapses of neuromyelitis optica. In: Clinical and Experimental Neuroimmunology. 2015 ; Vol. 6, No. 4. pp. 413-418.
@article{8d5c6e0bb54a4180bc61e2515dd9db00,
title = "Bevacizumab is safe in acute relapses of neuromyelitis optica",
abstract = "Objectives Neuromyelitis optica (NMO) is a relapsing autoimmune disease targeting the spinal cord and optic nerve leading to paralysis and blindness. Current treatment for acute NMO attacks is immunosuppression with high-dose corticosteroids and/or plasmapheresis. Preclinical animal studies suggest that bevacizumab might be beneficial in limiting the extent of inflammation during a NMO relapse by reducing the disruption of the blood-brain barrier. Methods We carried out an open-label phase 1b safety and proof-of-concept trial in 10 participants with NMO immunoglobulin G seropositive NMO, NMO spectrum disease and those at high risk for developing NMO/NMO spectrum disease who presented with an acute attack of transverse myelitis, optic neuritis or brainstem inflammation. In addition to treating with 1 g of daily intravenous methylprednisolone, we infused 10 mg/kg of bevacizumab intravenously on day 1 of treatment. The primary outcome measure was safety and the secondary outcome measure was efficacy. Results Of the 10 participants enrolled, five presented with acute transverse myelitis, four with acute optic neuritis and one with a brainstem lesion. Bevacizumab was safe in all 10 participants, with only one serious adverse event within the 90-day follow up that was not attributed to the medication. Three patients recovered to pre-attack neurological function or better, and no patients required escalation to plasmapheresis. Conclusions Bevacizumab is a safe add-on therapy to high-dose corticosteroids for NMO/NMO spectrum disease patients presenting with an acute relapse.",
keywords = "aquaporin-4, bevacizumab, neuromyelitis optica, vascular endothelial growth factor",
author = "Mealy, {Maureen A.} and Kyong Shin and Gareth John and Michael Levy",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/cen3.12239",
language = "English (US)",
volume = "6",
pages = "413--418",
journal = "Clinical and Experimental Neuroimmunology",
issn = "1759-1961",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Bevacizumab is safe in acute relapses of neuromyelitis optica

AU - Mealy, Maureen A.

AU - Shin, Kyong

AU - John, Gareth

AU - Levy, Michael

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objectives Neuromyelitis optica (NMO) is a relapsing autoimmune disease targeting the spinal cord and optic nerve leading to paralysis and blindness. Current treatment for acute NMO attacks is immunosuppression with high-dose corticosteroids and/or plasmapheresis. Preclinical animal studies suggest that bevacizumab might be beneficial in limiting the extent of inflammation during a NMO relapse by reducing the disruption of the blood-brain barrier. Methods We carried out an open-label phase 1b safety and proof-of-concept trial in 10 participants with NMO immunoglobulin G seropositive NMO, NMO spectrum disease and those at high risk for developing NMO/NMO spectrum disease who presented with an acute attack of transverse myelitis, optic neuritis or brainstem inflammation. In addition to treating with 1 g of daily intravenous methylprednisolone, we infused 10 mg/kg of bevacizumab intravenously on day 1 of treatment. The primary outcome measure was safety and the secondary outcome measure was efficacy. Results Of the 10 participants enrolled, five presented with acute transverse myelitis, four with acute optic neuritis and one with a brainstem lesion. Bevacizumab was safe in all 10 participants, with only one serious adverse event within the 90-day follow up that was not attributed to the medication. Three patients recovered to pre-attack neurological function or better, and no patients required escalation to plasmapheresis. Conclusions Bevacizumab is a safe add-on therapy to high-dose corticosteroids for NMO/NMO spectrum disease patients presenting with an acute relapse.

AB - Objectives Neuromyelitis optica (NMO) is a relapsing autoimmune disease targeting the spinal cord and optic nerve leading to paralysis and blindness. Current treatment for acute NMO attacks is immunosuppression with high-dose corticosteroids and/or plasmapheresis. Preclinical animal studies suggest that bevacizumab might be beneficial in limiting the extent of inflammation during a NMO relapse by reducing the disruption of the blood-brain barrier. Methods We carried out an open-label phase 1b safety and proof-of-concept trial in 10 participants with NMO immunoglobulin G seropositive NMO, NMO spectrum disease and those at high risk for developing NMO/NMO spectrum disease who presented with an acute attack of transverse myelitis, optic neuritis or brainstem inflammation. In addition to treating with 1 g of daily intravenous methylprednisolone, we infused 10 mg/kg of bevacizumab intravenously on day 1 of treatment. The primary outcome measure was safety and the secondary outcome measure was efficacy. Results Of the 10 participants enrolled, five presented with acute transverse myelitis, four with acute optic neuritis and one with a brainstem lesion. Bevacizumab was safe in all 10 participants, with only one serious adverse event within the 90-day follow up that was not attributed to the medication. Three patients recovered to pre-attack neurological function or better, and no patients required escalation to plasmapheresis. Conclusions Bevacizumab is a safe add-on therapy to high-dose corticosteroids for NMO/NMO spectrum disease patients presenting with an acute relapse.

KW - aquaporin-4

KW - bevacizumab

KW - neuromyelitis optica

KW - vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84955171124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955171124&partnerID=8YFLogxK

U2 - 10.1111/cen3.12239

DO - 10.1111/cen3.12239

M3 - Article

VL - 6

SP - 413

EP - 418

JO - Clinical and Experimental Neuroimmunology

JF - Clinical and Experimental Neuroimmunology

SN - 1759-1961

IS - 4

ER -